Key Highlights
- Addex Therapeutics raised $2.8 million through its at-the-market (ATM) program with H.C. Wainwright.
- The raise involved selling 437,869 ADSs, representing 52.5 million underlying shares.
- The proceeds extend the company's cash runway to the fourth quarter of 2027.
- Shares outstanding increased to 210.3 million; shares closed down 9% at $3.85.
An At-The-Market Capital Raise
Addex Therapeutics Ltd (NASDAQ:ADXN) raised $2.8 million through its at-the-market (ATM) Equity program conducted with H.C. Wainwright. An ATM program allows a company to sell newly Issued Shares or American Depositary Shares (ADSs) incrementally into the existing trading market over time, rather than through a single, large underwritten offering, which can allow for more flexible, opportunistic capital raising as market conditions permit.
In this instance, Addex (NASDAQ:ADXN) sold 437,869 ADSs, representing 52.5 million underlying ordinary shares, to raise the $2.8 million in proceeds.
Impact on Cash Runway and Share Count
The company said the proceeds extend its cash runway to the fourth quarter of 2027, giving a clearer sense of how long current resources, together with this raise, are expected to fund operations before further financing may be required. As a direct consequence of the raise, Addex's (NASDAQ:ADXN) total shares outstanding increased to 210.3 million, reflecting the dilutive nature of an equity-based capital raise.
Balancing Runway Extension Against Dilution
ATM raises are a common financing tool for clinical-stage biopharmaceutical companies that need to fund ongoing development without committing to a single large financing event. The trade-off, as with any equity issuance, is dilution to existing shareholders' percentage ownership, weighed against the benefit of additional runway to reach future value-driving milestones.
Market Reaction
Addex Therapeutics (NASDAQ:ADXN) shares closed down 9% at $3.85 following the disclosure, a reaction consistent with how dilutive financings are frequently received even when they extend a company's operating runway.
How much did Addex Therapeutics raise and through what mechanism?
Addex Therapeutics (NASDAQ:ADXN) raised $2.8 million through its at-the-market (ATM) program with H.C. Wainwright.
How many shares were involved in the raise?
The company sold 437,869 ADSs, representing 52.5 million underlying shares.
How far does the raise extend the company's cash runway?
The proceeds extend Addex Therapeutics' cash runway to the fourth quarter of 2027.






Please wait processing your request...